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Abstract. Infection with certain types of human papilloma-
virus (HPV) has been associated with the development of 
cervical and anal cancer. Worldwide, the incidence of anal 
cancer has increased markedly. The present study aimed to 
evaluate the prevalence of HPV infection of the uterine cervix 
and anal canal in human immunodeficiency virus (HIV)‑ and 
non-HIV-infected risk populations. Cervical and anal HPV 
swabs and cytology samples were collected from 287 patients 
at the University Hospital of Munich, Germany between 2011 
and 2013. Patients were divided into HIV-negative controls 
(G1) and two risk groups, including HIV-negative patients with 
cytological abnormalities of the cervix (G2) and HIV-infected 
patients (G3). Data, including clinical parameters, were 
analysed. The risk groups had significantly more positive 
results for HPV in the anus (71.03 and 83.15% for G2 and G3, 
respectively), as compared with G1. The predominant HPV 
genotypes found in the anus were high-risk HPV genotypes, 
which were significantly correlated with concomittant cervical 
HPV findings. In the risk groups, a significant association 
between the cytological findings and HPV detection in the 
cervix was found, while the results of the anus revealed no 
significance. The results of the present study suggested that the 
prevalence of HPV infection in the anal canal of risk popula-
tions is high. Furthermore, patients with abnormal cervical 
cytology results and HIV-infected women, irrespective of their 
individual cervical findings, may have a risk of concomittant 
anal high-risk HPV infection. Based on the predominant HPV 
genotypes found in the study, HPV vaccination could reduce 
the incidence of anal cancer. Nevertheless, high-risk patients 
should be intensively screened for anal squamous intraepithe-
lial abnormalities to avoid invasive cancer stages.
Introduction
Infection with certain types of human papillomavirus (HPV) 
plays an important role in the development of cervical and 
anal cancer. In the sexually active population, HPV infec-
tion of the anogenital region can be found in >60% of 
individuals (1). Screening for cervical cancer is well estab-
lished, and is accompanied by a significant risk reduction 
in the incidence of that cancer type (2). During the patho-
genesis of cervical cancer, precursor lesions, such as anal 
intraepithelial neoplasia (AIN), can develop into invasive 
squamous cell carcinoma of the anus (3). The majority of 
anal malignancies are associated with a persistent infection 
with HPV (4).
Over the past few decades, the incidence of anal cancer 
has increased significantly, particularly in women (5,6). In a 
previous study, coexisting HPV infection of the cervix and 
anal canal was detected in human immunodeficiency virus 
(HIV)-negative patients (7). Risk populations include men 
who have sex with men and transplant recipients. Furthermore, 
HIV-infected patients showed a higher prevalence of 
HPV-associated anal dysplasia or anal cancer compared with 
the HIV-negative population (8). In addition, the overall risk 
was ~28-fold higher in the female HIV-infected population (8). 
Whether treatment with combined antiretroviral therapy 
(cART) is able to reduce the risk of anal dysplasia and anal 
cancer in this patient group is controversial; however, its 
ability to reduce the occurrence of cervical and anal cancer 
has been poor to date (9-11).
The effectiveness of anal cancer screening has not been 
sufficiently evaluated. Furthermore, the question of whether 
the development of anal cancer can be prevented by the 
sufficient treatment of high‑grade AIN alone has yet to be 
answered (2). At present, strategies for anal screening and 
the treatment of high-grade AINs are under investigation in 
randomized controlled studies (12,13). At the very least, the 
identification of risk factors, such as anal HPV infection, and 
the resulting short-term monitoring of high-risk populations, 
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may lead to the early detection of the precancer and invasive 
stages.
Generally the prevalence of intra-anal HPV infection in 
the general HIV-negative female population, as compared with 
high-risk populations such as HIV-infected or HIV-negative 
patients with HPV-associated cervical abnormalities, is 
unknown. Therefore, the present prospective, cross-sectional 
study aimed to evaluate the prevalence of cervical and anal 
HPV infection, as well as clinical risk factors, in general 
controls, as compared with risk populations for anogenital 
dysplasia, including HIV-negative patients with abnormal 
cervical cytology attending the clinic for colposcopy evalua-
tion and HIV-infected women.
Materials and methods
Study population. The prospective study included 
287 patients who attended the Cervical Disease Screening 
and Treatment Unit or the specialized Gynaecological 
Outpatient Clinic for HIV-infected women at the Department 
of Gynecology and Obstetr ics, Ludwig-Maximilian 
University of Munich (Munich, Germany) between 2011 
and 2013. Patients were divided into three groups, as 
follows: G1, which included HIV-negative patients without 
a history of abnormal cytological findings who underwent 
routine cervical cytological screening (low-risk, n=93); G2, 
which included HIV-negative patients who were sent to 
our colposcopy unit with at least one preceding abnormal 
Papanicolaou-smear result (high-risk, n=90); and G3, which 
included HIV-infected patients who underwent routine 
cervical cytological screening at our outpatient department 
for HIV-infected women (high-risk, n=104). None of the 
patients had received the anti-HPV vaccination or were diag-
nosed with condyloma acuminata. All patients completed 
an anonymous, self-administered questionnaire, which 
collected information regarding their age, medical history, 
country of origin, smoking status, history of anal intercourse, 
number of sexual partners, age of first sexual intercourse and 
current marital status. According to the HIV-related history 
Centers for Disease Control and Prevention classification 
system, current cluster of differentiation (CD)4+ counts and 
nadir, information related to the viral load and ART were 
collected. Written informed consent was obtained from 
all patients. The present study was approved by the Local 
Ethics Committee of the Ludwig-Maximilian University of 
Munich (approval no. 273-10).
Specimen collection. Cervical and corresponding intra-anal 
cytology and HPV samples were obtained from each patient, 
according to the study protocol. Smears for cytology were 
performed in-house using a moistened cotton swab and cyto-
brush for cervical samples, and a moistened cotton swab for 
intraanal samples; they were fixed with M‑Fix® spray fixative 
at room temperature (Merck KGaA, Darmstadt, Germany), 
stained according to the Papanicolaou protocol and evalu-
ated using Munich nomenclature II (14) by an experienced 
cytologist using light microscopy. For further evaluation, 
the results were transferred to the Bethesda system (15). For 
HPV detection, a separate swab was used for cervical and 
intraanal probes.
Detection and genotyping of HPV in clinical specimens. 
DNA was isolated and purified from the specimens using a 
commercial kit (QIAamp DNA Mini kit; Qiagen GmbH, 
Hilden, Germany), according to the manufacturer's protocol. 
Amplification of the L1‑open reading frame and genotyping 
of the HPVs were performed using the INNO-LiPA HPV 
Genotyping Extra Amp and the INNO-LiPA HPV Genotyping 
Extra kit (both from Fujirebio Europe, Gent, Belgium). Known 
HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59 and 68), as well as the genotypes 6, 11, 26, 40, 43, 44, 53, 
54, 66, 73, 70 and 82 were covered.
Statistical analysis. Statistical analyses were performed 
by STAT-UP Statistical Consulting & Services (Munich, 
Germany) using the R statistical package software, 
version 2.14.0 for Windows. The threshold of significance was 
set as P=0.05. Groups were compared using Mann-Whitney U, 
Kruskal-Wallis, Fisher's exact and χ2 tests. Significance levels 
in post hoc tests were Bonferroni-Holm adjusted.
Results
Patient characteristics. A total of 287 patients were included 
in the study and divided into three groups. The baseline char-
acteristics of the examined cohort are presented in Table I.
Anal HPV findings. The prevalence of anal HPV infection 
among the three analysed groups (G1‑G3) was significantly 
different; 50, 71 and 83% of G1, G2 and G3, respectively, 
had a positive result for HPV in the anus. As compared with 
G1, G2 (P=0.011) and G3 (P<0.001) showed significantly 
more anal HPV infections of any type, while the difference 
between the G2 and G3 risk groups was not significantly 
different (P>0.05).
After dividing HPV genotypes into high-risk and low-risk 
anal HPV types, high-risk HPV genotypes were found 
significantly more often in the anal samples from G2 (65%; 
P<0.001) and G3 (62%; P<0.001), as compared with those from 
G1 (28%). The difference between G2 and G3 with regard 
to high-risk anal HPV genotypes, as well as the differences 
between the three groups with regard to low-risk anal HPV 
genotypes, were not significantly different.
Cervical and anal HPV findings. Regarding the prevalence of 
different HPV genotypes in the cervix and anus, 13 high-risk 
HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59 and 68) and 11 low-risk HPV genotypes (6, 11, 44, 53, 54, 
66, 69, 70, 71, 74 and 82) were found. Fig. 1 illustrates the 
distribution of the different cervical and anal high-risk HPV 
genotypes in the analysed groups. In the risk groups (G2 and 
G3), the most prevalent anal high-risk HPV genotypes were 
genotypes 16 (G2, 27%; G3, 14%), 18 (G2, 4%; G3, 9%), 31 
(G2, 7%; G3, 12%), 51 (G2, 12%; G3, 15%) and 52 (G2, 16%; 
G3, 8%).
In all groups, a positive HPV result was associated with 
significant concomitant cervical and anal HPV infection of 
any type (all P<0.05). A positive result for HPV in samples 
from the cervix and anus was found in 29% of the analysed 
patients in G1, 68% in G2 and 56% in G3. The significant asso-
ciation between cervical and anal samples persisted even after 
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dividing HPV genotypes into high-risk and low-risk groups 
(both P<0.05).
With regard to individual HPV genotypes, there was a 
significant association between several high‑ and low‑risk 
HPV genotypes and cervical and anal findings in the three 
analysed groups. There was a significant association between 
the cervical HPV genotype and the anal HPV genotype for 4 
of the 5 predominant high-risk HPV genotypes found in G2 
and G3 (G2: HPV 16, P<0.001; HPV 18, P<0.001; HPV 31, 
P<0.001; HPV 51, P=0.006; G3: HPV 16, P<0.001; HPV 18, 
P<0.001; HPV 31, P=0.012; HPV 52, P=0.001). Overall 36% 
of the analysed patients had a negative HPV result in the 
cervix after being tested positive for any HPV in the anus. In 
G2, 19% of the patients tested positive for any HPV genotype 
in the anus (high-risk, 33%), while 67% of G3 tested posi-
tive for any HPV genotype in the anus (high-risk, 43%). The 
difference between G2 and G3 was statistically significant 
(P<0.05).
Table I. Baseline patient characteristics. 
 Whole cohort G1 G2 G3
Characteristic (n=287) (n=93) (n=90) (n=104) P-values
Age, years  37.59±9.04 39.74±9.78 33.61±7.52 39.11±8.51 G1 vs. G2, P<0.05;
     G2 vs. G3, P<0.05;
     G1 vs. G3, P>0.05
Origin      P<0.05
  Western Europe 61.8 65.6 95.4 37.2
  Eastern Europe 12.3 20.4 3.1   9.3
  Central/South America 4.0/10.9 1.5/4.7 1.5/0 2.3/38.4
  Africa 10.9   7.8 0 12.8
Smoking      P<0.05
  Yes 32.0 29.0 44.3 24.0
  No 68.0 71.0 55.7 76.0
Anal intercourse      P>0.05
  Yes 28.8 35.5 25.3 25.7
  No 71.2 64.5 74.7 74.3
Age at first sexual intercourse, years     P>0.05
  ≤15 20.0 18.5 14.9 25.7
  16-19 56.1 53.3 66.7 49.5
  20-24 21.4 25.0 16.1 22.8
  ≥25   2.5   3.2 2.3   2.0
Lifetime sex partners      P>0.05
  1   9.0 16.5 4.6   5.9
  2-5 46.2 42.9 46.0 49.5
  6-10 24.4 19.8 39.1 15.8
  >10 20.4 20.9 10.3 28.8
Marital status/stable partner     P>0.05
  Yes 81.4 84.8 86.2 74.3
  No 18.6 15.2 13.8 25.7
History of worst cytological      P>0.05
result of the cervix
  Not specified 44.3 92.9 21.4 19.6
  PAP 2   8.6   1.2 1.4 19.6
  PAP 3   3.9   2.4 4.3   4.9
  PAP 3D 33.1   3.5 65.7 35.3
  PAP 4a   0.4 0 0   1.0
  PAP 4b   9.7 0 7.2 19.6
Data are presented as the mean ± standard deviation or %. G1, HIV-negative patients who underwent routine cervical cytology screening; G2, 
HIV-negative patients with at least one abnormal cytological (Pap)-smear result of the cervix; G3, HIV-infected patients who underwent routine 
cervical cytology screening; PAP, Papanicolaou (Munich nomenclature II). 
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Cervical and anal cytology and HPV findings. Analysing the 
results of the cervical and anal cytological analysis for cervical 
and anal HPV detection, a significant association between the 
cervical cytology result and cervical HPV was detected in 
all groups (all P<0.05). The worse the results of the cervical 
cytology, the more patients in that group tested positive for 
any HPV genotype in the cervix. Regarding the association 
between the anal cytology results and anal HPV detection, the 
analysed groups revealed no significance (Table II).
Anal HPV findings and clinical parameters. A significant 
association was observed between the detection of anal HPV 
infection in the present study and the number of lifetime sex 
partners (P<0.001), history of abnormal cervical cytology 
(P=0.009) and the history of cervical HPV (P<0.001). None 
of the other analysed characteristics (age, origin, smoking, 
anal intercourse, age of first sexual intercourse or marital 
status) were significantly associated with anal HPV infection. 
Regarding the HIV-infected patients, only the CD4+ nadir was 
significantly associated with anal HPV (P=0.021). The current 
CD4+ count, current HIV viral load, and the use of cART were 
not significantly associated with anal HPV. The clinical aspects 
related to HIV infection in G3 are summarized in Table III.
Discussion
The incidence of HPV-related cancer of the anus has increased 
over the past several decades. Risk populations, including 
women with a history of genital neoplasia or HIV-infected 
patients, are known. Furthermore, methods for effective anal 
cancer screening are under investigation (13).
Consistently with a recent review by Stier et al (16), both 
high-risk groups in the present study (G2 and G3) tested posi-
tive for any HPV genotype in the anus more often than the 
controls (G1). Limited data exists regarding anal HPV infec-
tion in the non-immunosuppressed general population, with 
high variance in the prevalence of anal HPV detection itself, 
and the prevalence of anal HPV in HIV-uninfected high-risk 
patients compared with HIV-infected women (17,18). All 
predominant HPV genotypes found in the anus of the two 
risk groups in the present study were high-risk HPV geno-
types. Compared with cervical cancer, the incidence of 
anal cancer in the general population is low (19). It seems 
that anal colonisation with HPV is less likely to lead to cell 
abnormalities than cervical colonisation, although the differ-
ence in the carcinogenesis of these mucosal sites has yet to 
be completely evaluated. At least chronological differences 
can be assumed (18). Nevertheless, due to high prevalence 
of anal HPV infection, the detection and possible treatment 
of anal precancerous lesions could decrease the incidence of 
anal cancer.
Sufficient cervical screening reduces the incidence of inva-
sive cancer. At the same time, the prophylactic HPV vaccination 
reduces the incidence of HPV infection, assuming a reduction 
in the incidence of HPV-associated cancers (20). Prophylactic 
HPV vaccination is part of the individual immunisation 
schedule in many countries, although the country-specific 
performance varies considerably (21). Besides the effect 
on the uterine cervix, the quadrivalente HPV vaccine was 
demonstrated to prevent persistent anal HPV infection and 
anal intraepithelial lesions (22). The five most prevalent anal 
HPV genotypes found in the present study were HPV types 
Figure 1. Illustration of the cervical and anal high-risk HPV genotypes in the analysed groups. G1, HIV-negative patients who underwent routine cervical 
cytology screening; G2, HIV-negative patients with at least one abnormal cytological (Pap)-smear result of the cervix; G3, HIV-infected patients who under-
went routine cervical cytology screening; HPV, human papillomavirus; HIV, human immunodeficiency virus.
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16, 18, 31, 52 and 51. With the administration of the 9-valent 
HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58), the 
rising incidence of anal cancer could be prevented more effec-
tively.
It was reported that the detection rate of HPV in simultane-
ously collected cervical and anal specimens was comparable 
or even higher in the anus (16). Consistent with the literature, a 
significant association between the prevalence of concomitant 
low- and high-risk cervical and anal HPV in all investigated 
patient groups was detected in the present study. One third of 
the analysed patients who had a negative result for HPV in the 
cervix tested positive in the anus. Of the HIV-infected patients 
with a negative result for HPV in the cervix, 67% tested positive 
for HPV in the anus. The risk for concomitant HPV infection of 
the cervix and anus appeared to be likely. However, a negative 
HPV result in the cervix should not discount the performance 
of an anal HPV screening, particularly in high-risk patients.
Screening for cervical cancer is well established. The 
benefits of cytology‑based vs. HPV‑based cancer screening 
of different mucosal sites are under discussion (23). A signifi-
cant association between the cytology findings of the cervix 
and cervical HPV detection was found in the present study. 
Controversial results were published concerning the asso-
ciation between anal cytology and anal HPV prevalence. A 
previous study reported a suspicious anal cytology in <10% of 
women with lower genital tract dysplasia, while positive anal 
HPV results were detected in >50% (24). In the present study, 
a significant association between the cytological results of the 
cervix and HPV detection in the cervix was observed, while 
there was no significant association between the anal cytology 
results and positive anal HPV detection. Compared with the 
cervical findings, a correlation between anal HPV infection 
and a suspicious anal cytology is infrequently observed. To 
date, there have been no valid data concerning the efficacy 
on any type of anal cancer screening technique. Currently, 
the primary screening tool for anal HPV-associated disease 
is cytology. Although the performance of anal cytology is 
similar to cervical cytology, experience in interpreting anal 
samples is limited. Other techniques such as high-resolution 
Table III. Specific characteristics of HIV‑infected patients.
 G3 HIV-infected
Characteristic patients (n=104)
Current detectable viral load 2,772 (<20->100,000)
(copies/ml)
Taking cART
  Yes 89
  No 11
cART duration (years)
  Range 0-21
  Mean ± SD 8.2±5.6
Current CD4 count (cells/µl) 540 (34-1650)
Nadir CD4 count (cells/µl) 258 (1-994)
Data are presented as the mean (interquartile range) or %. G3, 
HIV-infected patients who underwent routine cervical cytology 
screening; cART, combined antiretroviral therapy; HIV, human 
immunodeficiency virus; CD4, cluster of differentiation 4; SD, 
standard deviation.
Table II. Percentage of patients who tested positive for HPV 
in association with the corresponding cytology results of the 
cervix and anus.
Cytology classification n % HPV P‑value
G1   
  Cervix   P<0.05
    PAP 2 (NILM) 78   24 
    PAP 3 (ASCUS) 12   58 
    PAP 3D (LSIL)   2 100 
  Anus   P>0.05
    PAP 2 (NILM) 64   45 
    PAP 3 (ASCUS)   6 100 
    PAP 3D (LSIL) 10   60 
G2
  Cervix   P<0.05
    PAP 2 (NILM) 15   56 
    PAP 3 (ASCUS)   9   82 
    PAP 3D (LSIL) 14   93 
    PAP 4a (HSIL) 25   96 
  Anus   P>0.05
    PAP 2 (NILM) 27   73 
    PAP 3 (ASCUS)   3   75 
    PAP 3D (LSIL) 17   71 
    PAP 4a (HSIL)   1 100 
G3
  Cervix   P<0.05
    PAP 2 (NILM) 21   42 
    PAP 3 (ASCUS) 15   63 
    PAP 3D (LSIL) 13 100 
    PAP 4a (HSIL)   6 100 
    PAP 4b (HSIL/cancer)   1 100 
    PAP 5 (cancer)   2 100 
  Anus   P>0.05
    PAP 2 (NILM) 62   83 
    PAP 3 (ASCUS)   4   67 
    PAP 3D (LSIL)   5 100 
    PAP 4a (HSIL)   1 100 
G1, HIV-negative patients who underwent routine cervical cytology 
screening; G2, HIV-negative patients with at least one preceding 
abnormal cytological (PAP)-smear result of the cervix; G3, 
HIV-infected patients who underwent routine cervical cytology 
screening; PAP, Papanicolaou using Munich nomenclature II; HPV, 
human papillomavirus; HIV, human immunodeficiency virus; 
NILM, negative for intraepithelial lesion or malignancy; ASCUS, 
atypical squamous cells of undetermined significance; LSIL, low 
grade squamous intraepithelial lesion; HSIL, high grade squamous 
intraepithelial lesion.
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anoscopy should be considered to verify the true rate of 
anal dysplasias, particularly in cytological-negative and 
HPV-positive anal samples from risk populations. Further 
studies on the evaluation and implementation of anal cancer 
screening are required (25).
Consistent with the literature, a significant association 
between the number of lifetime sex partners and the incidence 
of anal HPV infection was demonstrated in the present study. 
Anal intercourse itself was not a significant factor, as demon-
strated previously (26,27). The prevalence of concomitant 
low‑ and high‑risk cervical and anal HPV was significantly 
associated in all investigated patient groups. It is still 
unknown if there is a reservoir for HPV in the genito-anal 
area. Besides sexual transmission, the transfer of HPV 
between the different mucosal sites may occur as a result of 
autoinoculation or smear infection (28-30). Irrespective of 
their individual immune status, the majority of the analysed 
high-risk patients in the present study showed an compre-
hensive anogenital HPV colonisation at the time of specimen 
collection. It was postulated that some type of global immune 
dysregulation results in the persistence of HPV in the cervix 
and anus (31). Immunosuppression caused by HIV infection is 
associated with HPV-related malignancies and contributes to 
HIV pathogenesis (31). Regarding the HIV-infected patients 
in the present study, the current CD4 count, as well as the 
current HIV viral load, did not have a significant influence 
on anal HPV infection. The impact of CD4 count and HIV 
viral load was previously discussed controversially. The 
low number of HIV-infected women analysed in the present 
study could be an explanation for this discrepancy. However 
consistent with the findings of Hessol et al (17), in which 
women with lower CD4 cell counts were more likely to have 
detectable oncogenic and non-oncogenic HPV types, a low 
CD4 nadir was significantly associated with anal HPV detec-
tion in the present study. In a study by Cambou et al (32), a 
significant correlation between a low CD4 nadir and previous 
CD4 counts was detected, indicating an increased risk for 
anal dysplasia in HIV-infected women with a history of 
severe immune devastation. The increased prevalence of HPV 
infection in HIV-infected individuals seems to be associated 
with immunosuppression (33). A higher level of HPV replica-
tion in women with a compromised immune system due to 
HIV infection could be the reason for that fact (16). The exact 
mechanisms of HIV-HPV interactions are still under investi-
gation. A previous study by Palefsky (9) evaluated whether the 
use of cART has an influence on the prevalence of anal HPV 
infection by immune recovery, finding that it lead to a limited 
reduction in HPV prevalence and the regression of cervical 
intraepithelial neoplasia. Subsequently, it was demonstrated 
that the risk of persistent HPV infection in HIV-infected 
women under long-term cART was reduced due to sustained 
viral suppression and increased CD4 counts (34,35). The rela-
tively short duration of cART use in the present study did not 
have a significant effect on anal HPV reduction. Due to the 
increased lifespan of HIV-infected patients, a consistent ART 
seems to be important to reduce the incidence of acquired 
immunodeficiency syndrome-defining HPV-associated 
cancers, such as cervical or anal cancer.
The limitation of this study was the cross-sectional setting. 
It could not be determined how many of the HPV infections 
were transient. A type‑specific clearance of high‑ and low‑risk 
HPV genotypes in the majority of women over a 5-year mean 
follow-up detection period was reported (36). The exception 
was HPV type 16, and concomitant cervical infection with this 
genotype, which is found in the majority of cervical high-grade 
dysplasias, was associated with anal HPV persistence (36). 
Further studies are required to clear these facts.
In conclusion, the present study demonstrated that the 
prevalence of anal HPV infection in high-risk populations is 
high. Non-HIV-infected women with cervical dysplasia and 
HIV-infected women, irrespective of their individual cervical 
findings, had a high risk of concomitant anal HPV infection. 
Due to the increase in lifespan of HIV-infected women receiving 
cART, these patients should be seen as a lifetime risk popula-
tion for HPV-associated anal cancer. Based on the predominant 
HPV genotypes found, the HPV vaccination could reduce the 
incidence of anal cancer. Concomitant intense screening for 
cervical and anal dysplasias in high-risk populations should be 
offered as a matter of routine to avoid invasive stages.
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